Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/4/2009

Company Ends Year with Cash and Investments of $65.0 Million

RICHMOND, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2008 financial results and accomplishments and provided an outlook for 2009.

For the fourth quarter ended December 31, 2008, Sangamo reported a consolidated net loss of $2.6 million, or $0.06 per share, compared to a net loss of $6.7 million, or $0.17 per share, for the same period in 2007. As of December 31, 2008, the company had cash, cash equivalents marketable securities and interest receivable of $65.0 million.

Revenues for the fourth quarter of 2008 were $6.8 million, compared to $2.8 million for the same period in 2007. Fourth quarter 2008 revenues were primarily from Sangamo's enabling technology agreements in cell line engineering for protein production including $3.0 million related to a fully-paid non-exclusive license agreement with Pfizer Inc and revenues from Sangamo's agreement with Genentech, Inc., as well as Sangamo's agreements with Dow AgroSciences (DAS) and Sigma-Aldrich Corporation.

Research and development expenses were $6.7 million for the fourth quarter of 2008, compared to $7.9 million for the same period in 2007. The decrease in research and development expenses for the fourth quarter of 2008 was primarily due to reduced expenses related to clinical trials as studies of our drug SB-509 progressed. Non-cash stock-based compensation included in research and development expenses totaled $605,000 and $409,000 in the fourth quarter of 2008 and 2007, respectively.

General and administrative expenses were $2.3 million for the fourth quarter of 2008, compared to $2.5 million for the same period in 2007. Non-cash stock-based compensation included in general and admini
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
2. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
3. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
4. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
8. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
11. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Stage Product Targeting Life-threatening Hereditary ... to Host Conference Call at 10:30 A.M. Eastern Today to Discuss ... ... Incorporated,(Nasdaq: VPHM ) and Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP),today ...
... July 15 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC Bulletin ... firm specializing in the manufacture,research, development, marketing ... appointment of American Stock Transfer & Trust ... registrar, effective August 15, 2008.,AST, headquartered in ...
... Inc. (NYSE: CRY ),a biomaterials, medical device and ... results will be released on,Thursday, July 31, 2008. The ... 10:00 a.m. Eastern Time, July 31, 2008, to discuss ... by Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
Cached Biology Technology:ViroPharma To Acquire Lev Pharmaceuticals 2ViroPharma To Acquire Lev Pharmaceuticals 3ViroPharma To Acquire Lev Pharmaceuticals 4ViroPharma To Acquire Lev Pharmaceuticals 5ViroPharma To Acquire Lev Pharmaceuticals 6ViroPharma To Acquire Lev Pharmaceuticals 7ViroPharma To Acquire Lev Pharmaceuticals 8ViroPharma To Acquire Lev Pharmaceuticals 9China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008 2CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
(Date:4/22/2014)... University of Kentucky has discovered new methods to build ... The research, led by Peixuan Guo, professor and ... College of Pharmacy and Markey Cancer Center, is reported ... Polymer Material To Build Robust Structures with Defined Shape ... L. Jasinski. , The article, which will appear in ...
(Date:4/22/2014)... Many research projects study the effects of temperature and ... species. However, an important component of climate research, the ... UFZ in collaboration with their colleagues from the Universities ... data from the U.S. NASA space agency in such ... the influence of UV-B radiation on organisms. , The ...
Breaking Biology News(10 mins):RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2UV-radiation data to help ecological research 2
... guidelines being used by foresters and the timber industry ... trees., Maps developed by Laura Gray, a post-doctoral fellow ... climatically suitable habitat for tree species based on climate ... work, published recently in the journal Climatic Change ...
... HZB physicist Dr. Philippe Wernet, chemist Prof. Dr. Athina Zouni ... SLAC National Accelerator Laboratory and Dr. Junko Yano of the ... project. In spite of the fact that all ... of it. Because as part of photosynthesis, green plants, algae, ...
... become stiff after middle age, a new study has revealed., ... compensate for the effects of obesity. But after middle age, ... body fat rises potentially increasing the risk of dying ... of body fat may be related to the total number ...
Cached Biology News:Snap shots of 1 of life's central processes 2Body fat hardens arteries after middle age 2
... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
... Deletion Cosmid Cloning Kit enables you to ... and unbiased primary cosmid library of genomic ... deletion sublibraries. High efficiency cosmid library construction ... kit protocols. First, genomic DNA is randomly ...
... A sensitive and high speed ... or phosphatase activity and for screening of ... This kit is based on a fluorescence ... or radioactive label. The universal platform provides ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
Biology Products: